Silence Therapeutics Statistics
Total Valuation
SLNCF has a market cap or net worth of 204.01 million. The enterprise value is 19.71 million.
| Market Cap | 204.01M |
| Enterprise Value | 19.71M |
Important Dates
The next estimated earnings date is Thursday, March 13, 2025.
| Earnings Date | Mar 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +24.69% |
| Shares Change (QoQ) | +0.34% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 25.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 1.31 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.35 |
| EV / Sales | 0.36 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.23 |
Financial Position
The company has a current ratio of 11.14, with a Debt / Equity ratio of 0.00.
| Current Ratio | 11.14 |
| Quick Ratio | 10.36 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.00 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -58.08% and return on invested capital (ROIC) is -39.61%.
| Return on Equity (ROE) | -58.08% |
| Return on Assets (ROA) | -19.24% |
| Return on Invested Capital (ROIC) | -39.61% |
| Return on Capital Employed (ROCE) | -26.68% |
| Revenue Per Employee | 496,842 |
| Profits Per Employee | -520,399 |
| Employee Count | 109 |
| Asset Turnover | 0.27 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -80.27% in the last 52 weeks. The beta is 1.04, so SLNCF's price volatility has been similar to the market average.
| Beta (5Y) | 1.04 |
| 52-Week Price Change | -80.27% |
| 50-Day Moving Average | 1.74 |
| 200-Day Moving Average | 5.04 |
| Relative Strength Index (RSI) | 40.25 |
| Average Volume (20 Days) | 137 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.57 |
Income Statement
In the last 12 months, SLNCF had revenue of 54.16 million and -56.72 million in losses. Loss per share was -1.23.
| Revenue | 54.16M |
| Gross Profit | 39.37M |
| Operating Income | -62.07M |
| Pretax Income | -55.67M |
| Net Income | -56.72M |
| EBITDA | -61.33M |
| EBIT | -62.07M |
| Loss Per Share | -1.23 |
Balance Sheet
The company has 184.45 million in cash and 146,475 in debt, giving a net cash position of 184.30 million.
| Cash & Cash Equivalents | 184.45M |
| Total Debt | 146,475 |
| Net Cash | 184.30M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 167.79M |
| Book Value Per Share | 3.55 |
| Working Capital | 213.51M |
Cash Flow
In the last 12 months, operating cash flow was -84.68 million and capital expenditures -264,156, giving a free cash flow of -84.94 million.
| Operating Cash Flow | -84.68M |
| Capital Expenditures | -264,156 |
| Free Cash Flow | -84.94M |
| FCF Per Share | n/a |
Margins
Gross margin is 72.70%, with operating and profit margins of -114.62% and -104.74%.
| Gross Margin | 72.70% |
| Operating Margin | -114.62% |
| Pretax Margin | -102.79% |
| Profit Margin | -104.74% |
| EBITDA Margin | -113.25% |
| EBIT Margin | -114.62% |
| FCF Margin | n/a |
Dividends & Yields
SLNCF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.69% |
| Shareholder Yield | -24.69% |
| Earnings Yield | -27.80% |
| FCF Yield | -41.64% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
SLNCF has an Altman Z-Score of 2.77. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.77 |
| Piotroski F-Score | n/a |